Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort

Brent Appelman, Jetta J. Oppelaar, Lani Broeders, W. Joost Wiersinga, Hessel Peters‐Sengers, Liffert Vogt, Michiel Schinkel, David Buis, Kim Sigaloff, Paul Elbers, Daisy Rusch, Auke C. Reidinga, Hazra S. Moeniralam, Caroline E. Wyers, Joop P. van den Bergh, Suat Şimşek, Bastiaan van Dam, Niels C. van den Gritters, Nejma Bokhizzou, Kees Brinkman, Martijn D. de Kruif, Tom Dormans, Renée Douma, Lianne R. de Haan, Tsz Yeung Fung, Martijn BeudelScientific 2022 · DOI

TL;DR

This study reveals that patients hospitalized with COVID-19 and chronic kidney disease (CKD) face significantly higher mortality and readmission rates, even after accounting for other risk factors. The findings highlight a critical vulnerability in CKD patients, emphasizing the need for increased clinical awareness and tailored management strategies for this population.

What Problem Does This Paper Address?

The COVID-19 pandemic has underscored the importance of identifying and understanding risk factors for severe outcomes. Chronic kidney disease (CKD) has been recognized as a significant comorbidity, but the precise impact of varying CKD stages on COVID-19 mortality and readmission rates, especially in a comprehensive, multi-center setting, remained unclear. Previous research often focused on end-stage renal disease (ESRD) or kidney transplant recipients, leaving a gap in understanding the risks associated with earlier stages of CKD. This paper aims to fill that gap by systematically evaluating mortality and readmission rates across the spectrum of CKD stages in hospitalized COVID-19 patients.

Methods

The researchers conducted a multicenter, retrospective observational cohort study using data from the Dutch COVIDPredict cohort. This cohort included patients hospitalized with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection (CORADS score ≥ 4) between March 2020 and July 2021. Patients were categorized into groups based on their pre-admission CKD stage (using CKD-EPI formula and eGFR) or as controls ("no-CKD"). The primary outcome was a composite endpoint of all-cause mortality or readmission within a 12-week follow-up period. Statistical analyses involved comparing baseline characteristics, vital signs, and laboratory values across groups. Logistic regression was employed to adjust for potential confounders such as age, sex, ethnicity, number of comorbidities, and COVID-19 treatment wave.

Datasets

The study utilized data from the Dutch COVIDPredict cohort, which comprises hospitalized patients from eleven hospitals in the Netherlands. This dataset included patients with PCR-confirmed SARS-CoV-2 infection or highly suspected CT scan-based infection (CORADS score ≥ 4) admitted between March 2020 and July 2021.

Key Insights and Ideas

  • CKD is a pervasive risk factor across stages: The study strongly suggests that CKD, not just in its advanced stages, significantly elevates the risk of severe COVID-19 outcomes, including mortality and readmission.
  • Beyond ESRD: While kidney transplant (KTX) and dialysis patients are known to be at higher risk, this research highlights that even patients with earlier stages of CKD (stages 3a, 3b, and 4) experience a demonstrably increased risk.
  • CKD itself is the driver: The authors found that even after adjusting for numerous confounding factors, the increased risk associated with CKD persisted, suggesting that CKD itself, rather than just its associated comorbidities, is a direct contributor to worse COVID-19 outcomes.
  • KTX patients face a particularly high risk: The study identified a notably higher mortality and readmission rate in kidney transplant patients, even after full adjustment, underscoring their heightened vulnerability.

Key Results

  • A total of 4151 hospitalized COVID-19 patients were included, with 389 (9.4%) having a history of CKD.
  • In the unadjusted model, all CKD stages, except stage 5, were associated with significantly higher mortality and readmission rates compared to the "no-CKD" group.
  • After adjusting for confounding variables, patients with CKD stages 3a, 3b, and 4, as well as kidney transplant (KTX) patients, showed significantly increased odds ratios for death and readmission, ranging from 1.96 to 8.94 compared to patients without CKD.
  • The fully adjusted model showed that KTX patients had the highest odds ratio for the composite endpoint (4.95), indicating a substantial increase in risk.
  • While some complications like congestive heart failure and anemia were more frequent in CKD patients, these did not appear to be the primary drivers of the increased mortality and readmission rates.

Limitations and Future Work

The authors acknowledge several limitations:

  • eGFR as the sole severity measure: The study relied on eGFR staging for CKD severity and did not incorporate albuminuria, which is another crucial indicator of CKD severity and progression.
  • Exclusion of patients: A significant number of CKD patients (247) were excluded due to missing pre-admission creatinine values, potentially affecting the generalizability of findings to this subgroup.
  • Primary diagnosis of CKD: The impact of the underlying cause of CKD on COVID-19 outcomes was not studied due to incomplete data.
  • Potential for residual confounding: Despite extensive adjustments, the possibility of overestimation or underestimation of results due to unmeasured confounders remains.

Future work could involve incorporating albuminuria data, investigating the impact of specific CKD etiologies, and exploring the effectiveness of tailored interventions for CKD patients with COVID-19. The authors emphasize the need for clinicians to be aware of the increased vulnerability of CKD patients to severe COVID-19 outcomes.

Summary updated

Abstract

Chronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.
BibTeX
@inproceedings{appelman2022mortality,
  author = {Brent Appelman and Jetta J. Oppelaar and Lani Broeders and W. Joost Wiersinga and Hessel Peters‐Sengers and Liffert Vogt and Brent Appelman and Michiel Schinkel and David Buis and Kim Sigaloff and Paul Elbers and Daisy Rusch and Auke C. Reidinga and Hazra S. Moeniralam and Caroline E. Wyers and Joop P. van den Bergh and Suat Şimşek and Bastiaan van Dam and Niels C. van den Gritters and Nejma Bokhizzou and Kees Brinkman and Martijn D. de Kruif and Tom Dormans and Renée Douma and Lianne R. de Haan and Tsz Yeung Fung and Martijn Beudel and Martijn Beudel},
  title = {{Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease: a multicenter retrospective cohort}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-06276-7},
}
Figure